These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 18589304)

  • 41. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
    Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
    Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies.
    Griffiths GL; Goldenberg DM; Knapp FF; Callahan AP; Chang CH; Hansen HJ
    Cancer Res; 1991 Sep; 51(17):4594-602. PubMed ID: 1873804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
    Nückel H; Frey UH; Röth A; Dührsen U; Siffert W
    Eur J Pharmacol; 2005 May; 514(2-3):217-24. PubMed ID: 15910809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
    Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
    Elter T; Molnar I; Kuhlmann J; Hallek M; Wendtner C
    Leuk Lymphoma; 2008 Dec; 49(12):2256-62. PubMed ID: 19052972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
    Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract]   [Full Text] [Related]  

  • 53. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
    Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
    Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 57. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
    Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.